STAT+: Nvidia says a biological revolution is happening now. But is it?
SAN FRANCISCO — The small hotel meeting room was packed like a rush hour subway….
Category: biotechnology
STAT+: JPM 2024: FogPharma’s new CEO, Mathai Mamman, unveils ‘contrarian’ plan in oncology
SAN FRANCISCO — Six months into his tenure as CEO of cancer startup FogPharma, Mathai…
.jpg)
The Afghan father aided U.S. soldiers. Now Texas Medicaid won’t pay for his son’s gene therapy
On a sweltering day in August 2021, as the engines of a hulking C-17 cargo…
STAT+: GSK to acquire Aiolos Bio in $1.4 billion deal, picking up an experimental asthma drug
LONDON — GSK said Tuesday it would purchase the asthma-focused drug developer Aiolos Bio for…
This is the TLDR of JPM Day 1
In honor of JPM Week, you’re reading a special edition of our biotech newsletter, The…
STAT+: At JPM, biotech’s most prolific dealmaker sees a rosy 2024 for acquisitions
SAN FRANCISCO — Eric Tokat, biotech’s most prolific dealmaker, believes 2024 will be another strong…
STAT+: At JPM, Bristol’s new CEO appeals to history to try to soothe investors’ nerves
SAN FRANCISCO — Christopher Boerner has been the CEO of Bristol Myers Squibb for just two…
STAT+: The ADC hot streak continues: J&J to buy cancer drug developer Ambrx Biopharma
Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion,…
STAT+: Merck to acquire Harpoon Therapeutics for $680 million
Merck announced Monday it will acquire Harpoon Therapeutics and its pipeline of immune-based cancer drugs…
No pain data yet from Vertex, and sky high deal expectations at JPM 2024
Want to stay on top of the science and politics driving biotech today? Sign up to…
Why did Allogene cancel two clinical trials for its off-the-shelf cell therapy?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Illumina chief commercial officer leaves to lead liquid biopsy startup Delfi
Delfi Diagnostics, a startup devising new ways to use routine blood draws to detect early…
STAT+: Allogene to pursue new strategy for development of off-the-shelf cell therapy in blood cancer
Allogene Therapeutics is making unexpected changes to development plans for its off-the-shelf cell therapy for…
STAT+: Feng Zhang’s year-old CRISPR delivery startup Aera lays off quarter of staff
Aera Therapeutics, a startup launched by the CRISPR pioneer Feng Zhang last year to solve…
Why CG Oncology will be the first test of 2024’s IPO waters
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Feng Zhang, Grail founder join forces on new gene editing startup, Moonwalk
A new startup co-founded by CRISPR innovator Feng Zhang, a former executive at Grail and…
STAT+: Novo Nordisk enlists two Flagship biotechs to develop obesity, MASH drugs
Novo Nordisk may already have one blockbuster obesity drug in its portfolio, but the Danish…
STAT+: Burning questions for the 2024 JPM Healthcare Conference
The J.P. Morgan Healthcare Conference is upon us, bringing its frenetic meetings, crowded hallways, and…
STAT+: Veteran biotech entrepreneur Harvey Berger to lead startup Kojin Therapeutics
Veteran biotech entrepreneur Harvey Berger, who has been on the sidelines for the past five…
Anavex’s slow journey to failure
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Goldman Sachs launches $650 million fund for life science investments
Investment bank Goldman Sachs is jumping into the biotech world after raising $650 million to…
STAT+: A single drug and multiple study failures leave Anavex with nothing but cash
It took Anavex Life Sciences seven months to finally acknowledge the failure of a late-stage…
STAT+: LabCentral, a crucial incubator for local drug discovery, is slated to grow amid industry slowdown
CAMBRIDGE — Vietnamese-born entrepreneur Jean Pham is “graduating” from LabCentral, a biotech launchpad on the…
An ugly fight over care for the poor in Texas
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: 3 health policies states are taking on in 2024
For most states, the new year means a new legislative session. STAT’s taking a look…
STAT+: 3 FDA staffers to watch in 2024
WASHINGTON — The Food and Drug Administration has a lot on its plate in 2024…
STAT+: Bristol Myers will pay $4.1 billion for cancer startup RayzeBio
Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into…
STAT+: FDA alters warning label for Carvykti CAR-T, although link to secondary cancers is unclear
The Food and Drug Administration issued a change to the warning label for Legend Biotech…
The clock is ticking, and cytokinetics is running out of December
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Bristol Myers to purchase Karuna, maker of schizophrenia drug, for $14 billion
Bristol Myers Squibb said Friday that it will acquire Karuna Therapeutics, a developer of medicines…
Listen: 2023 in review, CEO report cards, and a look at the year ahead
What does it mean to a bad CEO? Can biotech endure another election year? And…
BioMarin appeases an activist
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Medical marijuana companies are using pharma’s sales tactics with little of the same scrutiny
WASHINGTON — Medical marijuana companies sell medicine, just like pharmaceutical companies. But they’re not playing…
STAT+: Drugs are still mostly tested in white men. Will the FDA change that next year?
WASHINGTON — Sometime next year drug and medical device companies will have to tell the…
STAT+: In another blow, Argenx antibody therapy fails in trial for skin blistering condition
LONDON — The Belgian company Argenx said Wednesday that its closely watched antibody therapy failed…
STAT+: 3 trends to watch in biotech in 2024
Every winter, like Punxsutawney nobles, biotech’s many thought leaders gather in San Francisco to pick…
The biotech updates you need to read today
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: In the U.S., scientists see barriers to the development of CAR-T therapies. In Spain, a hospital brews its own
BARCELONA, Spain — Some of the patients waiting in the oncology ward of a hospital…
Here are the worst biopharma CEOs of 2023
Pfizer is this year’s anti-Eli Lilly. If David Ricks is the best biopharma CEO of…
STAT+: Prime Medicine, Mukherjee’s Myeloid Therapeutics clash over genome-editing deal
The closely watched gene editing startup Prime Medicine is embroiled in a multimillion-dollar dispute with…
The legal pathway for experimental, ultra-rare disease treatments is rocky and expensive
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Structure Therapeutics GLP-1 pill cuts blood sugar, weight in early diabetes study
Structure Therapeutics said Monday that its experimental GLP-1 pill demonstrated a 1% lowering of blood…
STAT+: Here are the best biopharma CEOs of 2023
It’s that time of the year again when I recognize the Best Biopharma CEO of…
STAT+: Illumina says it will divest Grail, starting a closing chapter for a disastrous deal
Illumina, the leading maker of DNA sequencing machines, said Sunday that it would divest Grail,…
FDA chastens pet companies over antibiotics
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: European regulators endorse Casgevy, paving way for approval of CRISPR-based therapy
LONDON — The world’s first medicine based on the genome-editing technology CRISPR will almost certainly…
Listen: FTC v. biotech, Pfizer’s kitchen sink, & Vertex’s future
Is no one safe from the FTC? Has Pfizer bottomed out? And is biotech finally…
STAT+: Jay Bradner, former Novartis research leader, to head up Amgen’s scientific efforts
Jay Bradner, a former top research leader at Novartis, is joining Amgen as its new…
.jpg)
Is it time to worry about Moderna?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: After decade-long dispute over CRISPR-Cas9, Editas strikes deal with Vertex to cash in
For a decade, leading academic institutes and their associated companies fought a bruising, headline-grabbing fight…